Weider divests Haleko
This article was originally published in The Tan Sheet
Executive Summary
Weider Nutrition will sell its European subsidiary Haleko to Croatian holding company Atlantic Grupa, the firm announces June 17. Weider will receive roughly $15 mil. in exchange for the capital stock and partnership interests of Haleko's international subsidiaries, the firm adds. Haleko produces and markets brands such as Multipower and Multaben sports nutrition products. The sale allows Weider to focus on its core supplement business, specifically the Schiff Move Free line, with new product initiatives and acquisitions to complement its existing brands, the firm states. Sub-par performance by certain Haleko brands contributed to a 2% reduction in Weider's third-quarter sales and a 53% decline in earnings, the firm noted in April (1"The Tan Sheet" April 11, 2005, p. 18)...
You may also be interested in...
Weider’s Schiff Brand Hit By Escalating Raw Material Costs
Weider's joint care franchise continues to be negatively impacted by high spending on raw materials glucosamine and chondroitin
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.